The reality of the island’s immune systems to combat the epidemic is unknown to this day by the World Health Organization
Abdullah, over time, maintains his safety, efficacy, and immune response to Covid. (Photo: PL)
Abdullah’s Cuban vaccine is the first antiviral immunogen in Latin America and the Caribbean, a fact that has been forgotten to this day by the World Health Organization (WHO) by not including it on the list for emergency use.
Since last July, the drug has been authorized for emergency use by the national regulatory entity, after demonstrating 92.28 percent efficacy in preventing symptoms of disease and 90 percent efficacy in critically ill patients affected by the SARS-CoV-2 coronavirus. .
Likewise, it showed a 99.15 percent increase in antibodies in volunteers aged 3 to 11 and 98.28 percent in those aged 12 to 18 participants in the Ismailo clinical trial conducted in the central province of Camagüey.
The Center for Genetic Engineering and Biotechnology (CIGB), the innovator of immunity, confirmed that the increase in antibody titers was four times or more than the first dose of the drug in these populations.
The clinical trial concluded on October 14, with 500 children participating, and two formulations with an potency of 25 and 50 mcg of Al-Abdullah, on a schedule ranging from 0-14-28 days.
The principal investigator of the studies on this vaccine, Sonya Resek, highlighted at the time that more than 80 percent of the adverse events reported in children were mild and that the rest of the indications were comparable with data obtained in adults, a fact that confirmed its efficacy.
With these findings, Cuban health authorities have allowed a large-scale vaccination campaign, as well as use among the population aged two to 11, since last October, a decision that made this Caribbean country the world’s first to protect children. Girls and teens from Covid-19.
On the other hand, Abdullah’s vaccine, over time, maintains its safety, efficacy and immune response to the Corona virus, which confirms its suitability for booster doses, said Dr. Verina Mozio Gonzalez, Director of Clinical Research at CIGB.
He explained that the immune response was higher in people who had already been vaccinated with three injections of this drug and in other cases with Sinopharm (China) and Sputnik (Russia), when intervening last November in the Roundtable Radio TV space.
He determined that the results of the clinical trial with convalescent patients without any antiviral drug, which was conducted at the Hermanos Amigiras Clinical Surgical Hospital in this city, were satisfactory.
Hence the approval of the State Control Center for Medicines, Equipment and Medical Devices (Cecmed) to be applied as a booster dose in people who have more than five months of vaccination.
Since last November 7, Abdullah’s booster dose has been applied in the Cuban capital for health workers, a strategy that has been gradually expanded to other sectors of the population.
Delivery of just over six million doses is expected to speed up this process due to the emergence of the Omicron variant of the SARS-CoV-2 virus, which causes the disease.
The Caribbean island also contains the immunomodulators Soberana 02 and Soberana Plus, from the Finlay Vaccine Institute, to combat the Covid epidemic, and two candidate vaccines (Soberana 01 and Mambisa) are in the clinical trial phase with significant results, according to official sources.
Countries such as Venezuela, Nicaragua, Iran, and Vietnam provide Cuban vaccines to their residents.
This fact is not known by the World Health Organization (WHO), when added to the emergency use list, the recombinant drug Vaxzevria (AZD1222) for the treatment of disease, jointly produced by Argentina and Mexico, used in some countries and with this approval would facilitate its acquisition and production.
The biological vaccine, from the Anglo-Swedish pharmaceutical company AstraZeneca, was developed by the Argentine company mAbxience and Mexican Laboratorios Liomont and according to the American Health Organization (PAHO), making it the “first” vaccine in Latin America.
It has been added to the immunosuppressive preparations Covaxin, Covishield, Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca, Sinovac (CoronaVac) and Sinopharm approved by the international health entity.
“Unapologetic tv specialist. Hardcore zombie trailblazer. Infuriatingly humble problem solver.”